Pablo Oppezzo

Institut PasteurFrance

Dr Pablo Oppezzo received his MSc in Molecular and Cellular Biology from PEDECIBA (Uruguay) in 1999. In 2004, he received his PhD in Immunology from the University Paris VI, and did post-doctoral work at the Biochemical Structural Unit at the Pasteur Institute of Paris. In 2006 he obtained a position as Principal Investigator of Recombinant Protein Unit at Institut Pasteur de Montevideo, Uruguay. Dr Pablo Oppezzo is now the Head of the Recombinant Protein Unit and Professor in the Immunology department at the School of Medicine, Republic University (UdelaR), Uruguay. Dr Oppezzo’s research focuses on the mechanisms involved in the origins of haematopoietic B-cell malignancies, specifically the study of the mutagenic action of the enzyme Activation-Induced cytidine deaminase. In the last years, he contributed to elucidate the mechanism of somatic hypermutation and class switch recombination process in Chronic Lymphocytic Leukemia and to identify new prognosis markers for this disease.

1books edited

2chapters authored

Latest work with IntechOpen by Pablo Oppezzo

B-cell chronic lymphocytic leukemia (CLL) is considered a single disease with extremely variable course, and survival rates ranging from months to decades. It is clear that clinical heterogeneity reflects biologic diversity with at least two major subtypes in terms of cellular proliferation, clinical aggressiveness and prognosis. As CLL progresses, abnormal hematopoiesis results in pancitopenia and decreased immunoglobulin production, followed by nonspecific symptoms such as fatigue or malaise. A cure is usually not possible, and delayed treatment (until symptoms develop) is aimed at lengthening life and decreasing symptoms. Researchers are playing a lead role in investigating CLL's cause and the role of genetics in the pathogenesis of this disorder. Research programs are dedicated towards understanding the basic mechanisms underlying CLL with the hope of improving treatment options.

Go to the book